Home  »  Stocks to Invest   »  Valneva SE (VALN) Stock Exhibits Minor Volatility ...

Valneva SE (VALN) Stock Exhibits Minor Volatility Ahead of Positive Topline Results from Cov-Compare Trial

Valneva SE (VALN) stock prices were down by 9.72% as of the market closing on October 19th, 2021. This brought the price per share down to USD$35.40. Subsequent premarket fluctuations saw the stock rise by 8.56%, bringing it up to USD$38.43.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

Cov-Compare Trial

October 18th, 2021 saw VALN stock announce positive topline results from the Phase 3 pivotal trial Cov-Compare. The trial is designed to evaluate the company’s inactivated, adjuvanted Covid-19 vaccine candidate, VLA2001. The clinical study recruited a total of 4,012 participants above the age of 17 across a total of 26 trial sites across the United Kingdom. The trial met its co-primary endpoints, the first of which was the demonstration of VLA2001’s superiority against AZD1222 in terms of geometric mean titer for neutralization antibodies. The second co-primary endpoint was the exhibition of non-inferiority in terms of seroconversion rates at two weeks after the second vaccination, on day 43 of the regimen, in adults above the age of 29.

Details of the Trial

T-cell responses analyzed in a sub-set of participants showed the treatment having induced broad antigen-specific IFN-gamma producing T-cells reactions against the S-, N-, and M- protein. The treatment was generally well-tolerated, with its tolerability profile of VLA2001 being substantially more favorable as compared to the active comparator vaccine. Participants above the age of 29 reported experiencing substantially reduced solicited adverse events within seven days of the vaccination. This is both in regard to injection site reactions and systemic reactions. No unsolicited treatment-related SAEs were reported, while less than 1% of the patient population reporting an adverse event of special interest in either treatment group.

VALN Stock Seeks Approval

VALN stock initiated rolling submission for initial approval with the United Kingdom’s Medicines and Healthcare products Regulatory Agency. The company is taking steps to prepare for the rolling submission for condition approval with the European Medicines Agency. A prerequisite for the final submission of the clinical study report is a final assay validation required by the MHRA. This assay validation serves to verify the integrity of the VLA2001-301 data, with the process currently underway.

Future Outlook for VALN Stock

The company is keen to push for the accelerated development and commercialization of its proprietary VLA2001 treatment. VALN stock is poised to capitalize on the momentum being generated around the world in regard to VLA2001. Current and potential investors are confident in management’s ability to effectively leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

385

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam